Phosphodiesterase type 5 inhibitor use among pregnant and reproductive-age women in the United States.

Purpose: To assess the prevalence and potential indications of PDE5 inhibitor use among pregnant and reproductive-age women in the United States.

Methods: We identified women 15 to 50 years with a livebirth from January 2001 through March 2018 in Sentinel Database. We assessed the prevalence of PDE5 inhibitor use prior to and during pregnancy by trimester, identified potential on- and off-label indications using predefined diagnosis codes recorded within 90 days before the estimated last menstrual period through delivery.